Home・Aktien・Organon & Co

Organon & Co

Geschlossen

BrancheGesundheitswesen

13.77

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.77

Max

13.77

Schlüsselkennzahlen
By Trading Economics
Einkommen	-292M -146M
Verkäufe	98M 1.6B
KGV Branchendurchschnitt	17.641 56.659
EPS	0.8
Dividendenrendite	0.58
Gewinnspanne	-9.355
Angestellte	10,000
EBITDA	-38M 371M

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	0.58% 2.18%
Nächstes Ergebnis	9. Nov. 2026
Nächste Dividendenausschüttung	10. Sept. 2026
Nächstes Ex-Dividendendatum	19. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	63M 3.6B
Vorheriger Eröffnungskurs	13.77
Vorheriger Schlusskurs	13.77

Nachrichtenstimmung

By Acuity

75%

25%

306 / 339 Ranking in Healthcare

Organon & Co Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Organon & Co Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Organon & Co – Dist abgegeben haben.

Stimmung

By Acuity

306 / 339 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.